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Background: Genetic factors are thought to be crucial in the pathogenesis of ankylosing spondylitis.
Transforming growth factor b1 (TGFb1) is a multifunctional cytokine that plays a key role in inflammation.
Two functional single nucleotide polymorphisms (SNPs) in the TGFB1 gene have been described: TGFB1
T869C and TGFB1 G915C.
Objective: To determine whether these SNPs contribute to ankylosing spondylitis susceptibility or its
disease characteristics.
Methods: Genomic DNA was isolated from the peripheral blood of 134 patients with ankylosing
spondylitis and 194 healthy blood donors. All subjects were unrelated and of white Dutch ethnicity. The
diagnosis of ankylosing spondylitis was made according to the modified New York criteria. The TGFB1
T869C and TGFB1 G915C SNPs were genotyped by a polymerase chain reaction–single strand
conformation polymorphism haplotyping method.
Results: No significant differences were found between patients and controls in genotype, allele, and
haplotype frequencies or in the carrier rate of the rare alleles of the TGFB1 T869C and TGFB1 G915C
SNPs.
Conclusions: TGFB1 T869C and TGFB1 G915C SNPs are not major factors in the susceptibility to
ankylosing spondylitis or its disease characteristics.
A
nkylosing spondylitis (AS) is a common familial
rheumatic disorder. The disease is characterised by
chronic inflammation of the sacroiliac joints and the
vertebral column. The inflammatory process leads gradually
to fibrosis and calcification of the spine and sacroiliac joints.
Ultimately, ossification, interosseous bridging, and ankylosis
can occur. Spinal osteoporosis is often observed in patients
with active disease and is probably induced by regulatory
cytokines.1 2
The precise aetiology of the disorder remains unclear,
though heritability plays a major role. Twin studies suggest
that up to 97% of the susceptibility to AS can be attributed to
genetic factors.3 For over 30 years the main known genetic
component has been human leucocyte antigen (HLA) B27.
More than 95% of white patients with primary AS and at
least 50% of those with AS associated with psoriasis or
inflammatory bowel disease are HLA-B27 positive, whereas
HLA-B27 is present in only 8% of the general Dutch
population.4
However, family studies have shown that the major
histocompatibility complex (MHC), including HLA-B27,
contributes less than 40% to the recurrence risk ratio in
AS.5 Apart from the MHC, Laval et al identified six other
loci—on chromosomes 1p, 2q, 9q, 10q, 16q, and 19q—that
are linked to AS. The peak of linkage on chromosome 19 was
observed with the marker D19S420 (LOD score 3.58).5
The TGFB1 gene encoding the human transforming growth
factor b1 (TGFb1) is located 1.8 Mb from marker D19S420 on
chromosome 19q13.6 TGFb1 is a multifunctional cytokine
involved in the regulation and proliferation of cells. This
cytokine promotes differentiation of leucocytes, but has
inhibitory effects on proliferation of T lymphocytes and
activation of macrophages, suggesting a regulatory role in
inflammatory states.7 TGFb1 is known to be able to control
the production of many components of the extracellular
matrix and to be a potent regulator of osteoblast proliferation
and differentiation.8 In general, TGFb stimulates cartilage
and bone formation, but the precise effects are complex,
depending on the concentration of TGFb, whether the bone is
growing or damaged, the state of activation of the cells, and
the presence of other factors, including hormones.9 Moreover,
TGFb is required to switch B cells into production of IgA,10 11
which is often increased in AS patients.12 Therefore, TGFb is a
good candidate for a key cytokine in an inflammatory disease
such as AS, in which new bone formation and ultimately
ankylosis of the sacroiliac joints and the vertebral column are
major symptoms and fibrosis is a related phenomenon.13–15
Recently, the single nucleotide polymorphisms (SNPs) at
positions +869 (TRC) and +915 (GRC) in the signal protein
sequence of the TGFB1 gene, which change codon 10
(Leu10Pro) and codon 25 (Arg25Pro), respectively,16 have
been reported to be related to variations in the production of
TGFb1, both in vitro17 and at the serum level.18
In the present study we investigated whether the TGFB1
T869C and TGFB1 G915C SNPs or their haplotypes are
associated with susceptibility to or disease characteristics of
AS.
METHODS
Subjects
After informed consent, 134 AS patients were recruited from
the outpatient department of rheumatology of the Jan van
Abbreviations: HLA, human leucocyte antigen; HWE, Hardy–
Weinberg equilibrium; MHC, major histocompatibility complex; SNP,
single nucleotide polymorphism; TGFb1, transforming growth factor b1
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Breemen Institute. They all fulfilled the diagnostic require-
ments of AS according to the modified New York criteria.19
Controls were 194 randomly selected healthy blood donors
from the Amsterdam region. All subjects were unrelated and
of white Dutch ethnicity.
PCR-SSCP analysis
A polymerase chain reaction–single strand conformation
polymorphism (PCR-SSCP) method was optimised for the
simultaneous detection of the SNPs at positions +869 and
+915 in the TGFB1 gene and their haplotypes. The method
has been described previously by Garcı´a-Gonza´lez et al.20 In
that study in a Dutch population, the alleles were shown to
form three haplotypes, denoted as haplotype 1 (TGFB1+
869T2TGFB1+915G), haplotype 2 (TGFB1+869C2TGFB1+
915G), and haplotype 3 (TGFB1+869C2TGFB1+915C). In
brief, the region containing the SNP at position +869 (NCBI
SNP CLUSTER ID: rs1982073) and the SNP at position +915
of the TGFB1 gene (NCBI SNP CLUSTER ID: rs1800471) was
amplified by PCR in a Perkin-Elmer 9600 thermal cycler
(Perkin-Elmer, Norwalk, Connecticut, USA) according to the
following parameters: 97 C˚ for 90 seconds, 61 C˚ for 90
seconds, and 72 C˚ for 60 seconds for three cycles, followed
by 32 cycles of 97 C˚ for 30 seconds, 61 C˚ for 60 seconds,
and 72 C˚ for 60 seconds, with a final elongation at 72 C˚ for
10 minutes.
PCR products diluted twofold in 99% formamide were
heated at 95 C˚ for three minutes and placed on ice.
Electrophoresis on a pre-cast non-denaturing 20% polyacry-
lamide PhastGel at 20 C˚ and silver staining were done semi-
automatically on the PhastSystemTM (Amersham Pharmacia,
LKB Biotechnology AB, Uppsala, Sweden).
Statistical analysis
Allele and genotype frequencies were tested for Hardy–
Weinberg equilibrium (HWE) by the x2 test. To compare
frequencies x2 testing was used or, when appropriate, Fisher’s
exact test. A two sided p value of ,0.05 was considered
significant. The magnitude of association was expressed as
the odds ratio (OR) with 95% confidence intervals (CI). The
statistical analyses were undertaken using SPSS 10.0 for
Windows.
RESULTS
Characteristics of the 134 AS patients are summarised in
table 1. Genotype and distribution of allele frequencies in AS
patients and controls for the TGFB1 T869C and TGFB1 G915C
polymorphism are shown in table 2.
The data for the controls were published previously by
Schrijver et al.21 The genotype frequencies in the control group
did not deviate from HWE equilibrium. No significant
differences were observed between AS patients and controls
in the frequencies of the carriership of the allele TGFB1 869C
(OR=0.96 (95% CI, 0.69 to 1.33), p=0.81) and the allele
TGFB1 915C (OR=1.62 (0.93 to 2.84), p=0.09) (table 2);
neither were significant differences observed between AS
patients and controls in the frequencies of the carriership of
the three TGFB1 haplotypes (table 3).
No significant associations were found between carriage of
either of the alleles TGFB1 869C and TGFB1 915C, or their
haplotypes, and sex, past or present peripheral arthritis or
acute anterior uveitis, age at first complaints, years between
these first complaints and the diagnosis of AS, and the
number of patients with at least one first degree family
member with AS (data not shown).
DISCUSSION
In this study the TGFB1 T869C and TGFB1 G915C SNPs or
their haplotypes were not significantly associated with
susceptibility to AS or its manifestations in a white Dutch
population. Genotype and allele frequencies of the TGFB1
T869C and TGFB1 G915C SNPs in our control population
were similar to those reported in some European studies
undertaken in healthy controls from Northern Ireland and
France16 and from the United Kingdom,17 22 23 as summarised
by Garcı´a-Gonza´lez et al.20
Eight polymorphisms have been identified in TGFB1: three
in the upstream region of the gene at positions 2988, 2800,
and 2509 from the transcription start site; one in the non-
translated region at position +72; two non-synonymous
coding SNPs in the signal peptide sequence: TGFB1 T869C
which changes codon 10 (Leu10RPro), and TGFB1 G915C
which changes codon 25 (Arg25RPro); one SNP in the region
of the gene coding for the precursor part of the protein is not
present in the active form: TGFB1 C1632T which changes
codon 263 (Thr263RIle); and a one base pair deletion in
intron 4 (713-8delC).16 24 The TGFB1 promoter polymorph-
isms and the T869C variant account for most of the diversity
at this locus and a relatively small increase in diversity is
Table 1 Demographic and clinical characteristics of
patients with ankylosing spondylitis (n = 134)
Characteristic Frequency
Age (years)* 50.9 (12.9) (19 to 79)
Age at first complaints (years) 23.0 (19.0 to 31.5)
Age at diagnosis (years)* 34.7 (10.6) (16 to 63)
Years between first complaints and diagnosis 7.0 (2.0 to 12.5)
Women 18.7%
HLA-B27 positive 94%
Iridocyclitis 43%
Peripheral arthritis 41%
First degree relatives with AS 28%
*Mean (SD) (range).
Median (interquartile range).
AS, ankylosing spondylitis.
Table 2 TGFB1 genotype and allele frequencies in patients with ankylosing spondylitis and controls
Genotype
Controls (n = 194) Patients (n = 134)
OR (95% CI)n (%) AF n (%) AF
TGFB1 T869C
TT 80 (41.2) 65.5 57 (42.5) 64.6
0.96 (0.69 to 1.33) (p = 0.81)TC 94 (48.5) 59 (44.0)
CC 20 (10.3) 34.5 18 (13.4) 35.4
TGFB1 G915C
GG 168 (86.6) 93.3 107 (79.9) 89.6
1.63 (0.93 to 2.84) (p = 0.09)GC 26 (13.4) 26 (19.4)
CC 0 6.7 1 (0.7) 10.4
AF, allele frequency; CI, confidence interval; OR, odds ratio.
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attributable to the rare variants TGFB1 C1632T and TGFB1
G915C.25
The TGFB1 polymorphism 713-8delC is more frequent in
patients with osteoporosis than in normal controls and seems
to be associated with very low bone mass in osteoporotic
women and with low bone mass and increased bone turnover
in both osteoporotic and healthy women.24 As bone mineral
density is often decreased in AS patients, TGFB1 polymorph-
isms seem to be of even more interest in this disease.
In a Japanese study, the frequency of the allele TGFB1 869T
was found to be significantly higher in subjects with osteo-
porosis than in healthy individuals.26 On the other hand, the
TGFB1 869C allele was associated with an increase in osteo-
porosis in white Australian women.27 The TGFB1 869C allele
has also been associated with ossification of the posterior
longitudinal ligament in the cervical spine and with spinal
osteophytosis in Japanese patients.28 29 The development of
spinal osteophytes is also a characteristic feature of AS.
The TGFB1 915G allele is strongly associated with fibrotic
lung disease.17 Apical pulmonary fibrosis is rare but well
recognised in patients with AS.13 No association between
Crohn’s disease or ulcerative colitis, which are clinically
related to AS, and TGFB1 SNPs had been found in previous
studies.20 30
The genotype TGFB1 915GG has been related to higher
serum concentrations of TGFb1 in a previous study.17 A
combined study from Finland and the United Kingdom
found a weak association between age of symptom onset of
AS and the TGFB1 G915C SNP.25 Furthermore, this study
noted a weak positive association of the rare allele TGFB1
1632T with AS and also with a younger age at symptom onset
of AS. These investigators concluded from their study that
‘‘the polymorphisms (G–800A, C–509T, T+869C, G+915C and
C+1632T) in the TGFB1 gene play at most a small role in AS
and that other genes on chromosome 19 are involved in the
susceptibility to AS’’.25
The results from our study do not show an association
between the TGFB1 G915C SNP and AS, although the
frequency of allele TGFB1 915G was greater in AS patients
than in controls, but this difference did not reach significance
(p=0.09). In our group of AS patients no association
between the TGFB1 G915C SNP and a younger age of
symptom onset of AS could be found.
As TGFb may play a crucial role in the pathogenesis of AS,
especially in new bone formation, further research is
necessary to elucidate the role of TGFb1 in this disease, and
possibly open the way towards new pharmacological
approaches for preventing the most disabling phenomenon
of this disorder, ankylosis.
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